Speakers - 2026

Title: Changes in Visual Evoked Potential and Optical Coherence Tomography in Parkinson’s Disease: A Systematic Review and Meta-Analysis

Abstract

Past studies show that both optical coherence tomography (OCT) and visual evoked potential (VEP) are impaired in Parkinson’s disease (PD), but the results have been all over the map—inconsistent and conflicting. So, this meta-analysis took a smarter approach through only included studies that ran both tests on the same patients. After reviewing nearly, a number of studies covering over 330 PD patients and 270 healthy controls, the picture clears up. the VEP P100 latency was significantly delayed in PD patients. The signal moves slower. Next, the retinal nerve fiber layer (RNFL) was significantly thinner—a clear structural loss. Two other measures—P100 amplitude and central foveal thickness—showed no significant difference. Most importantly, they found a strong negative link: the thinner the retinal layer, the slower the VEP signal. This tells us these two tests are measuring related damage. In conclusion, OCT and VEP capture real, connected neurodegeneration in PD. They’re promising biomarkers but pick your metrics wisely—latency and RNFL thickness are the key players, not amplitude.

What will the audience take away from presentation?

• RNFL Thinning is a Robust Structural Biomarker
• VEP P100 Latency Delays Reflect Functional Impairment
• Structure and Function Are Tightly Linked